A Phase 1/1b Study of MPT-0118 in Subjects with Advanced or Metastatic Solid Tumors.
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.
The study will be conducted in 3 parts:
- Part A: MPT-0118 dose-escalation
- Part B: MPT-0118 dose-escalation in combination with pembrolizumab
- Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Inclusions/Exclusion: ECOG 0-1. Measurable disease by RECIST. PD after or on at least 1 systemic therapy in adv/mets setting. No prior tx with MALT1 inhibitor. No history of stroke, seizure disorder or myocarditis. No CNS, lepto, or brain mets. No HIV, or active HCV/HBV.